Effect of Ondansetron for Withdrawal Symptoms
Information source: Stanford University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Substance Withdrawal Syndrome
Intervention: Ondansetron (Drug)
Phase: N/A
Status: Enrolling by invitation
Sponsored by: Stanford University Official(s) and/or principal investigator(s):
Sean Mackey, Principal Investigator, Affiliation: Stanford University
Summary
We hope to determine whether Ondansetron, an anti-nausea medication, works to help relieve
withdrawal symptoms experienced while the patient is being weaned off opioid medications.
This medication has shown anecdotal evidence of being affective for the treatment of
withdrawal symptoms and we hope to determine whether this is affective.
Clinical Details
Official title: Effect of Ondansetron for Withdrawal Symptoms
Study design: Treatment, Non-Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Primary outcome: Decrease of withdrawal symptoms
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:-Over 18 years of age
- No medical contraindications to medication
- Able to fulfill research procedures Exclusion Criteria:-Subjects who are unable to
respond to our questionnaires or to stimuli as required by the experimental protocol
will be excluded.
- Subjects will be excluded if they have a history of significant psychiatric disorders
that would prevent them from engaging in a treatment program.
- Participating in other studies that would interfere with the procedures in this study
- Known or apparent pregnancy
Locations and Contacts
Stanford University School of Medicine, Stanford, California 94305, United States
Additional Information
Starting date: May 2008
Last updated: June 16, 2008
|
